A comprehensive approach to type 2 diabetes mellitus – A recommendation document

Reyes-García, Rebeca; Moreno-Pérez, Óscar; Tejera-Pérez, Cristina; Fernández-García, Diego; Bellido, Virginia; Casares, Martín López de la Torre; Rozas-Moreno, Pedro; Fernández-García, José Carlos; Martínez, Amparo Marco; Martı́n, Javier; Gargallo-Fernández, Manuel; Botana-Lopez, Manuel Antonio; López-Fernández, Judith; González-Clemente, José Miguel; Jódar-Gimeno, Esteban; Mezquita-Raya, Pedro

doi:10.1016/j.endien.2018.10.013

Cited by 10 publications

(11 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the 34 sites that enrolled patients account for approximately half of the communities/regions within Spain, so may not be representative of the entire population. Furthermore, in Spain, GLP-1RAs are only reimbursed for patients who have a BMI ≥ 30 kg/m 2 , and only approximately 8% of Spanish patients with T2D are prescribed GLP-1RAs [ 11 , 47 ]. Therefore, none of the patients enrolled in the study had a ‘normal’ BMI (≥18.5–<25 kg/m 2 ).…”

Section: Discussionmentioning

confidence: 99%

“…In addition to their glucose-dependent function resulting in a low risk for hypoglycaemia [ 7 ], some GLP-1RAs (dulaglutide, liraglutide, and semaglutide) have demonstrated cardiovascular (CV) benefits in patients with T2D at high risk of CV disease [ 8 , 9 , 10 ]. Despite these benefits, access to GLP-1RAs is limited in Spain, and GLP-1RAs are only reimbursed for patients with obesity (body mass index [BMI] ≥ 30 kg/m 2 ) and insufficient glycaemic control as a second-line therapy after metformin [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

Bellido

Padín

Catarig

et al. 2022

JCM

View full text Add to dashboard Cite

Type 2 diabetes (T2D) is a complex disease for which an individualised treatment approach is recommended. Once-weekly (OW) semaglutide is a glucagon-like peptide-1 receptor agonist approved for the treatment of insufficiently controlled T2D. The aim of this study was to investigate the use of OW semaglutide in adults with T2D in a real-world context. SURE Spain, from the 10-country SURE programme, was a prospective, multicentre, open-label, observational study, approximately 30 weeks in duration. Adults with T2D and ≥1 documented HbA1c value ≤12 weeks before semaglutide initiation were enrolled. Change in HbA1c from baseline to end of study (EOS) was the primary endpoint, with change in body weight (BW), waist circumference, and patient-reported outcomes as secondary endpoints. Of the 227 patients initiating semaglutide, 196 (86.3%) completed the study on-treatment with semaglutide. The estimated mean changes in HbA1c and body weight between baseline and EOS were −1.3%-points (95% confidence interval (CI) −1.51;−1.18%-points) and −5.7 kg (95% CI −6.36;−4.98 kg). No new safety concerns were identified. Therefore, in routine clinical practice in Spain, OW semaglutide was shown to be associated with statistically significant and clinically relevant reductions in HbA1c and BW in adults with T2D.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

Bellido

Padín

Catarig

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…In general terms, disease modifying therapies should be used in combination with metformin, that is, with benefit in morbidity -associated mortality, low risk of hypoglycemia, and benefits in terms of control of BP and excess of weight (if appropriate) [6].…”

Section: Comprehensive Pharmacological Treatment In the Elderly With T2dmmentioning

confidence: 99%

Diabetes in Older People: Comprehensive Approach

Moreno-Pérez¹,

Tejera

Reyes-García³

2020

ADO

View full text Add to dashboard Cite

The clinical management of older people with diabetes requires a comprehensive evaluation and a holistic approach for the individualization of objectives and strategies of treatment. In older people with diabetes, geriatric syndromes, frailty and sarcopenia are considered at present as a third category of chronic complications. These situations are added to traditional microvascular and macrovascular complications, leading to significant disability and increasing the costs. In this context, two clinical scenarios can be considered: the first one, elderly subjects without significant comorbidities and good functional condition, in which an approach to diabetes similar to that of younger patients must be made. The second scenario, elderly and frail subjects, in which it will be essential a correct identification of these conditions and the evaluation of geriatric syndromes. This evaluation will guide the adaptation in the goals of treatment and in global management of diabetes. Some basic principles should guide our decision-making: starting drugs at low -medium doses, with progressive increase according to tolerability; selection of drugs according to evidence-based medicine (considering the limited evidence in this age group), favoring agents with the lowest risk of hypoglycemia, avoid polypharmacy. Finally, patient´s safety and quality of life should be the main objectives.

show abstract

“…Among all these subtypes, T2DM is the biggest threat to public health, the figure for T2DM patients almost accounting for 90% of the total 6 . A wide range of diabetes therapies including behavioral 7 , nutritional 8 , physical 9 and the most important, medicamentous therapies, have been adopted to alleviate diabetes and its complications.…”

Section: Introductionmentioning

confidence: 99%

Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems

Ding

Zhang

et al. 2021

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

A comprehensive approach to type 2 diabetes mellitus – A recommendation document

Cited by 10 publications

References 62 publications

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study

Diabetes in Older People: Comprehensive Approach

Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems

Contact Info

Product

Resources

About